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Evolving Concepts on Human SMN Pre-mRNA Splicing
Abstract
SMN1 and SMN2 represent two nearly identical copies of the Survival Motor Neuron gene in humans.
Deletion of SMN1 coupled with the inability of SMN2 to compensate for the loss of SMN1 leads to Spinal
Muscular Atrophy (SMA), a leading genetic cause of infant mortality. SMN2 holds the promise for cure of
SMA if skipping of exon 7 during pre-mRNA splicing of SMN2 could be prevented. Previous reports have
shown that a C to T mutation at the 6th position of exon 7 (C6U substitution in the transcript) is the primary
cause of SMN2 exon 7 skipping. Cumulative evidence suggests that C6U abrogates an enhancer associated
with SF2/ASF, as well as, creates a silencer associated with hnRNP A1. There is also evidence to suggest that
C6U creates an extended inhibitory context (Exinct). Recently, an intronic hnRNP A1 motif, which is not
conserved between two human SMN genes, have been implicated in skipping of SMN2 exon 7. However,
mechanism by which two SMN2-specific hnRNP A1 motifs interact is not known. Systematic approaches
including site-specific mutations, in vivo selections, RNA structure probing and antisense oligonucleotide
microwalks have revealed additional cis-elements in exon 7 as well as in flanking intronic sequences. A unique
intronic splicing silencer (ISS-N1) has emerged as an effective target for correction of SMN2 exon 7 splicing
by short antisense oligonucleotides (ASOs). Low nanomolar concentrations of ASOs against ISS-N1 fully
restored SMN2 exon 7 inclusion and increased levels of SMN in SMA patient cells. Such a robust antisense
response could be due to accessibility of the target as well as the complete nullification of a strong inhibitory
impact rendered by ISS-N1. Bifunctional oligonucelotides with capability to recruit stimulatory splicing
factors in the vicinity of weak splice sites of exon 7 have also shown promise for correction of SMN2 exon 7
splicing. Considering an antisense-based strategy confers a unique advantage of sequence specificity,
availability of many target worthy cis-elements holds strong potential for antisense-mediated therapy of SMA.
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AbbReviAtioNS
ASO antisense oligonucleotide
C6U a cytosine to uridine mutation at the 
 6th position of SMN2 exon 
Exinct extended inhibitory context
ISS-N1 intronic splicing silencer N1
SMA spinal muscular atrophy
SMN survival motor neuron gene
TSL terminal stem loop  
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AbStRAct
SMN1 and SMN2 represent two nearly identical copies of the survival motor neuron 
gene in humans. Deletion of SMN1 coupled with the inability of SMN2 to compensate 
for the loss of SMN1 leads to spinal muscular atrophy (SMA), a leading genetic cause of 
infant mortality. SMN2 holds the promise for cure of SMA if skipping of exon 7 during pre-
mRNA splicing of SMN2 could be prevented. Previous reports have shown that a C to T 
mutation at the 6th position of exon 7 (C6U substitution in the transcript) is the primary 
cause of SMN2 exon 7 skipping. Cumulative evidence suggests that C6U abrogates 
an enhancer associated with SF2/ASF, as well as, creates a silencer associated with 
hnRNP A1. There is also evidence to suggest that C6U creates an extended inhibitory 
context (Exinct). Recently, an intronic hnRNP A1 motif, which is not conserved between 
two human SMN genes, has been implicated in skipping of SMN2 exon 7. However, 
mechanism by which two SMN2-specific hnRNP A1 motifs interact is not known. 
Systematic approaches including site-specific mutations, in vivo selections, RNA structure 
probing and antisense oligonucleotide microwalks have revealed additional cis-elements 
in exon 7 as well as in flanking intronic sequences. A unique intronic splicing silencer 
(ISS-N1) has emerged as an effective target for correction of SMN2 exon 7 splicing by 
short antisense oligonucleotides (ASOs). Low nanomolar concentrations of ASOs against 
ISS-N1 fully restored SMN2 exon 7 inclusion and increased levels of SMN in SMA 
patient cells. Such a robust antisense response could be due to accessibility of the target 
as well as the complete nullification of a strong inhibitory impact rendered by ISS-N1. 
Bifunctional oligonucelotides with capability to recruit stimulatory splicing factors in the 
vicinity of weak splice sites of exon 7 have also shown promise for correction of SMN2 
exon 7 splicing. Considering an antisense-based strategy confers a unique advantage of 
sequence specificity, availability of many target worthy cis-elements holds strong potential 
for antisense-mediated therapy of SMA.
SMN1 and SMN2 represent two nearly identical copies of the survival motor neuron 
gene in humans.1 SMN1 predominantly produces full-length transcripts, whereas SMN2 
mostly produces transcripts lacking exon . Full-length SMN protein (the product of 
full-length transcript) is absolutely necessary for the survival of all higher eukaryotes.2 
Deletion of SMN1 coupled with the inability of SMN2 to compensate for the loss of 
SMN1 leads to spinal muscular atrophy (SMA), the second most common autosomal 
recessive genetic disorder in humans.1-3 It is generally believed that correction of SMN2 
exon  splicing holds the promise for cure of SMA. However, this requires a full under-
standing of SMN2 exon  splicing. Comparison between SMN1 and SMN2 revealed a 
critical C to T mutation at the 6th position (C6U transition in transcript) of exon  of 
SMN2. C6U is sufficient to cause SMN exon  skipping.4,5 SMN2 exon  seems to have 
a weak 3´ splice site (3´ss). Consistently, an improved polypyrimidine tract (PPT), which 
defines the 3´ss, restored inclusion of SMN2 exon .6 However, an improved PPT is not 
sufficient to compensate for the loss of a purine-rich exonic splicing enhancer (ESE) in the 
middle of exon .6 This ESE was identified as the binding site for splicing factor Tra2-b1. 
Over expression of Tra2-b1 or associated factors hnRNP G and SRp30c restores inclusion 
of SMN2 exon .8,9 Also, STAR (Signal Transduction and Activation of RNA) family 
of proteins have been implicated in tissue-specific regulation of SMN exon  splicing.10 
Recent reports reveal new and rather unique cis-elements and provide an advanced under-
standing of SMN exon  splicing.
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Evolving Concepts on Human SMN Pre-mRNA Splicing 
competiNg modelS foR SiNgle mutAtioN cAuSiNg exoN 
7 SKippiNg
Mechanism by which C6U promotes SMN2 exon  skipping 
remains a complex issue. Theoretically, C6U could create one or a 
combination of situations including but not limited to abrogation 
of an enhancer, creation of a silencer, disruption of a stimulatory 
RNA structure and strengthening of an inhibitory RNA structure.2 
Based on in vitro experiments, an initial study supported an enhancer 
model.11 According to this model, C6U abrogates an essential ESE 
associated with splicing factor SF2/ASF. Proponents of this model 
have recently presented additional data to support a direct role of 
SF2/ASF in SMN1 exon  splicing.12 However, a critical evidence 
against SF2/ASF model came from an in vivo experiment in which 
absence of SF2/ASF in a chicken cell line did not cause the antici-
pated skipping of SMN1 exon .13 This finding may suggest that any 
direct (or indirect) role of SF2/ASF is replaceable by other splicing 
factors in case of SMN1 exon  splicing. Results obtained from 
chicken cell line paved the way for a competing model in which 
C6U creates an exonic splicing silencer (ESS) associated with splicing 
factor hnRNP A1.13 According to this model, binding of hnRNP 
A1 to SMN2 exon  causes exon  skipping. Strongest evidence in 
support of hnRNP A1 model came from RNA interference (RNAi) 
experiment in which depletion of hnRNP A1 promoted exon  
inclusion in SMN2.13 However, RNAi results left open the possibility 
of a cumulative effect of multiple hnRNP A1 targets. Indeed, a recent 
report has confirmed the existence of another functional hnRNP A1 
motif within intron  of SMN2.14
Evolutionary relevant single mutations tend to have multidi-
mensional consequences. In case of C6U, it is likely that loss of 
an enhancer is accompanied by the gain of a silencer. In addition, 
C6U may strengthen an inhibitory RNA structure, TSL1 (terminal 
stem loop 1), which is formed by sequences at the 5' end of exon 
 (Fig. 1).15 Consistently, numerous mutations in the vicinity of 
C6U supported an Extended inhibitory context or Exinct model.15 
Additional evidence in support of Exinct model came from a 
recent and rather very systematic study in which several antisense 
oligonucleotides (ASOs) that blocked 
Exinct region promoted SMN2 exon  
inclusion.16 In an interesting way, this 
ASO-based approach revisited the issue of 
enhancer versus silencer model associated 
with C6U. The fact that ASO-mediated 
targeting of regions encompassing C6U 
restores SMN2 exon  inclusion supports 
the role of a silencer. However, due to 
constraints of target accessibility and some 
discrepancies between in vitro and in vivo 
results, interpretations of antisense study 
should be treated with caution.
multiple exoNic ciS‑elemeNtS 
coNtRibute towARd exoN 7 
SpliciNg
To analyze all exonic cis-elements that 
modulate SMN exon  splicing, a novel 
approach of in vivo selection was used.1-19 
This approach applied the principle of 
mutability to determine the relative signif-
icance of all residues within exon . The highly mutable positions 
were considered as inhibitory, whereas the conserved positions were 
considered as stimulatory for exon  inclusion. Based on mutability 
plot, three major regulatory elements were determined (Fig. 1). 
Among them are Exinct and 3'-Cluster, the negative elements located 
towards the 5' and 3' ends of exon , respectively. “Conserved tract” 
is the third element, which plays a stimulatory role, and is located 
in the middle of exon . Here again, independent validation of 
cis-elements determined by in vivo selection came from the recently 
reported ASO-based approach.16 For example, ASOs that blocked 
inhibitory regions covering Exinct or 3'-Cluster promoted exon  
inclusion, whereas ASOs that blocked stimulatory regions covering 
Conserved tract promoted exon  exclusion.
One of the surprising outcomes of in vivo selection of entire exon 
 was the revelation that the 5'ss of exon  is extremely weak.1 This 
was apparent from the overwhelming selection of a nonwild type G 
residue at the last position (54G) of exon . The impact of 54G was 
so profound that it promoted SMN2 exon  inclusion even in the 
absence of Tra2-b1-ESE.1 Preference for a nonwild type G over wild 
type A at the last position of exon  could be due to increase in size of 
the duplex formed between the 5'ss and U1 snRNA (abbreviated as 
5'ss:U1 duplex). Stimulatory impact of a long 5'ss:U1 duplex at the 
5'ss of exon  has been recently confirmed.20 In addition to a small 
size of 5'ss:U1 duplex, other factors contribute towards a weak 5'ss 
of exon . Significant among them is an inhibitory RNA structure, 
TSL2 (terminal stem loop 2), formed by the last 1 residues of exon 
 and the first two residues of intron  (Fig. 1). Breaking of TSL2 
promoted SMN2 exon  inclusion, whereas strengthening of TSL2 
promoted skipping of exon  even in SMN1.20 Compensatory muta-
tions provided the ultimate proof of inhibitory role of TSL2. For 
example, 40G and 54C mutations separately promoted SMN2 exon 
 inclusion by breaking TSL2, whereas together these mutations led 
to a complete skipping of SMN2 exon  by restoring and strength-
ening TSL2.20
Figure 1. Diagrammatic representation of SMN exon 7 and adjacent intronic sequences. Sequences 
highlighted in red indicate negative cis-elements, whereas sequences highlighted in green indicate 
positive cis-elements. Capital letters represent exonic and small-case letters represent intronic nucleotides. 
*represents 6th exonic position that is C in SMN1 and U in SMN2. U1 snRNA binding site is indicated 
along with positive (+) and negative (-) cis-elements, which promote and inhibit exon 7 inclusion, respec-
tively. Exinct, Conserved tract and 3'-Cluster were discovered by in vivo selection of the entire exon 7.17 
Binding sites for splicing factors SF2/ASF, hnRNP A1 and Tra2-b1 have been described by others.7,11-13 
ISS-N1 is a novel cis-element with strong negative effect.23 RNA structures TSL1 and TSL2 have been 
confirmed by enzymatic probing.20
8 RNA Biology 2006; Vol. 4 Issue 1
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Role of iNtRoNic RegulAtoRy elemeNtS iN SMN2 exoN7 
SKippiNg
The 54-nucleotide long human SMN exon  is flanked by a 
large upstream intron 6 (~6kb) and a relatively short downstream 
intron  (~0.5kb). Exon trapping assay revealed a negative element 
(element 1) in intron 6 and a positive element (element 2) in intron  
(Fig. 2).21,22 Recently, a strong intronic splicing silencer, ISS-N1, 
has been identified in intron  (Figs. 1 and 2).23 Inhibitory nature of 
ISS-N1 was confirmed by three independent approaches i.e., deletion, 
mutation and ASO-mediated blocking. In case of SMN1, deletion of 
ISS-N1 compensates for the loss of element 2 and Tra2-b1-ESE.23 
These results demonstrate that large intronic cis-elements, which are 
often impossible to predict, could have profound impact on exon 
definition. Also, these results suggest that unique intronic cis-ele-
ments such as ISS-N1 may have evolved to balance the stimulatory 
effects of positive cis-elements or vice versa. Similar to 3'-Cluster and 
TSL2, ISS-N1 is absent in mice. All three elements (3'-Cluster, TSL2 
and ISS-N1) are in close proximity to the 5'ss (Fig. 2). One of the 
possible mechanisms by which ISS-N1 exerts its role could be the 
sequestration of the 5'ss through active collaborations with 3'-Cluster 
and TSL2. Presence of Exinct, which includes a putative binding site 
for hnRNP A1, may act as a facilitator of this process.
The finding that an additional hnRNP A1 motif is created in 
SMN2 due to a single mutation in intron  suggests for the first 
time that a difference between SMN1 and SMN2 in the noncoding 
region also contributes towards SMN2 exon  skipping.14 This new 
hnRNP A1-ISS is located one hundred nucleotides downstream of 
SMN2 exon . Degree of negative impact of this hnRNP A1-ISS in 
the context of endogenous SMN2 has not been examined. In fact, an 
ASO-based approach would be the next logical experiment to eval-
uate and validate the negative impact of hnRNP A1-ISS. Mechanism 
by which two SMN2-specific hnRNP A1-binding sites are brought 
together may demand looping out of intervening sequences.14 A 
similar situation could be envisioned for element 1, which is located 
~100 nucleotides upstream of exon .21 Looping out mechanisms, 
which are yet to be proved, may in fact involve complex interactions 
that bring distantly located negative elements in close proximity 
(Fig. 2). As an alternative to the looping out mechanisms, it is 
possible that each negative element acts independently at different 
stage of a rather dynamic process of exon definition.
The fact that blocking of ISS-N1 by an ASO improved inclusion 
of SMN2 exon  suggests that inhibitory impact of C6U is subser-
vient to other negative cis-elements that participate in making the 
5'ss of exon  very weak. In addition, negative impact of C6U could 
be overcome by a variety of tailed ASOs that anneal to exon  in 
the vicinity of splice sites.24-2 Mechanisms by which these bifunc-
tional ASOs promote SMN2 exon  inclusion involve recruitment 
of SF2/ASF and/or other splicing factors.24-2 Antisense microwalks 
reported recently will provide ideal annealing positions for the devel-
opment of future bifunctional ASOs.16 Since SMN exon  is the last 
coding exon, removal of the downstream intron  is not essential 
for making full-length SMN. Consistently, an ASO that prevented 
intron  removal by blocking the 3'ss of exon 8 produced more SMN 
from SMN2.28 This finding confirms that inhibitory effect of C6U, 
which weakens the 3'ss of exon , is realized only in the context of 
a strong 3'ss of the downstream exon (exon 8). To a broader signifi-
cance, it has become clear that none of the negative cis-elements have 
irreversible impact on SMN2 exon  skipping. To a direct therapeutic 
significance, most of the reported negative cis-elements could be 
targeted by ASOs. For example, low doses (in low nanomolar range) 
of ASOs against ISS-N1 fully restored SMN2 exon  inclusion and 
increased levels of SMN in SMA patient cells. Such a robust anti-
sense response could be due to accessibility of the target as well as 
the complete nullification of a strong inhibitory impact rendered by 
ISS-N1. Published reports reveal a wide variety of small compounds 
with potential to restore SMN2 exon  inclusion in SMA.3 But, an 
ASO-based strategy, which confers a unique advantage of sequence 
specificity, holds a strong promise for SMA therapy.
coNcludiNg RemARKS
In recent years SMN exon  splicing has become a model system 
to understand alternative splicing in a human disease. Initial studies 
began with the quest for simple mechanisms by which C6U muta-
tion promotes SMN2 exon  exclusion. Subsequent studies led to the 
discoveries of multiple cis-elements as potential therapeutic targets. 
Significantly, most of these cis-elements are context specific and 
are not predictable by available computational programs. Unique 
functional approaches and analysis tools, which helped reveal these 
elements, will have future implications for studies of other human 
diseases associated with aberrant splicing.
References
 1. Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud 
C, Millasseau P, Zeviani M, LePaslier D, Frezal F, Cohen D, Weissenbach J, Munnich A, 
Melki J. Identification and characterization of a spinal muscular atrophy-determining gene. 
Cell 1995; 80:1-5.
 2. Singh NN, Androphy EJ, Singh RN. The regulation and regulatory activities of alternative 
splicing of the SMN gene. Crit Rev Eukaryot Gene Expr 2004; 14:21-85.
 3. Wirth B, Brichta L, Hahnen E. Spinal muscular atrophy and therapeutic prospects. Prog 
Mol Subcell Biol 2006; 44:109-32.
 4. Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN gene regu-
lates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA 1999; 
96:630-11.
 5. Monani UR, Lorson CL, Parsons DW, Prior TW, Androphy EJ, Burghes AH, McPherson 
JD. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene 
SMN1 from the copy gene SMN2. Hum Mol Genet 1999; 8:11-83.
 6. Lorson CL, Androphy EJ. An exonic enhancer is required for inclusion of an essential exon 
in the SMA-determining gene SMN. Hum Mol Genet 2000; 9:259-65.
Figure 2. Diagrammatic representation of inhibitory cis-elements that promote 
SMN2 exon 7 skipping. Negative cis-elements are shown in red, whereas 
positive cis-elements are shown in green. Thick black lines delineate exon/
intron boundaries. Exinct, hnRNP A1 ESS, Tra2-ESE and 3'-Cluster are 
located in exon 7. Element 1 is located in intron 6, whereas ISS-N1, element 
2 and hnRNP A1 ISS are located in intron 7. Partial sequence of TSL2 is 
shown. The 5' ss of exon 7, representing Exon 7/ intron 7 junction, and U1 
snRNA-binding site are marked. As per one hypothesis, negative elements 
are brought together by looping out of intervening sequences.
www.landesbioscience.com RNA Biology 9
D
ow
nl
oa
de
d 
by
 [I
ow
a S
tat
e U
niv
ers
ity
] a
t 0
7:2
1 1
0 F
eb
ru
ary
 20
16
 
Evolving Concepts on Human SMN Pre-mRNA Splicing 
 . Hofmann Y, Lorson CL, Stamm S, Androphy EJ, Wirth B. Htra2-b1 stimulates an exonic 
splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 
(SMN2). Proc Natl Acad Sci USA 2000; 9:9618-23.
 8. Hofmann Y, Wirth B. hnRNP-G promotes exon  inclusion of survival motor neuron (SMN) 
via direct interaction with Htra2-b1. Hum Mol Genet 2002; 11:203-49.
 9. Young PJ, DiDonato CJ, Hu D, Kothary R, Androphy EJ, Lorson CL. SRp30c-dependent 
stimulation of survival motor neuron (SMN) exon  inclusion is facilitated by a direct interac-
tion with hTra2-b1. Hum Mol Genet 2002; 11:5-8.
 10. Stoss O, Novoyatleva T, Gencheva M, Olbrich M, Benderska N, Stamm S. P59(fyn)-mediated 
phosphorylation regulates the activity of the tissue-specific splicing factor rSLM-1. Mol Cell 
Neurosci 2004; 2:8-21.
 11. Cartegni L, Krainer AR. Disruption of an SF2/ASF-dependent exonic splicing enhancer 
in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat Genet 2002; 
30:3-384.
 12. Cartegni L, Hastings ML, Calarco JA, de Stanchina E, Krainer AR. Determinants of exon  
splicing in the spinal muscular atrophy genes, SMN1 and SMN2. Am J Hum Genet 2006; 
8:63-.
 13. Kashima T, Manley JL. A negative element in SMN2 exon  inhibits splicing in spinal 
muscular atrophy. Nat Genet 2003; 34:460-63.
 14. Kashima T, Rao N, Manley JL. An intronic element contributes to splicing repression in 
spinal muscular atrophy. Proc Natl Acad Sci USA 200; 104:3426-431.
 15. Singh NN, Androphy EJ, Singh RN. An extended inhibitory context causes skipping 
of exon  of SMN2 in spinal muscular atrophy. Biochem Biophys Res Commun 2004; 
315:381-88.
 16. Hua Y, Vickers TA, Baker BF, Bennett CF, Krainer AR. Enhancement of SMN2 exon  
inclusion by antisense oligonucleotides targeting the exon. PLoS Biol 200; 13:5(4):e3.
 1. Singh NN, Androphy EJ, Singh RN. In vivo selection reveals combinatorial controls that 
define a critical exon in the spinal muscular atrophy genes. RNA 2004; 10:1291-305.
 18. Buratti E, Baralle FE. Another step forward for SELEXive splicing. Trends Mol Med 2005; 
11:5-9.
 19. Singh RN. Unfolding the mystery of alternative splicing through a unique method of in vivo 
selection. Front Biosci 200; 12:3263-22.
 20. Singh NN, Singh RN, Androphy EJ. Modulating role of RNA structure in alternative 
splicing of a critical exon in the spinal muscular atrophy genes. Nucleic Acids Res 200; 
35:31-89.
 21. Miyajima H, Miyaso H, Okumura M, Kurisu J, Imaizumi K. Identification of a cis-acting 
element for the regulation of SMN exon  splicing. J Biol Chem 2002; 2:2321-.
 22. Miyaso H, Okumura M, Kondo S, Higashide S, Miyajima H, Imaizumi K. An intronic 
splicing enhancer element in survival motor neuron (SMN) pre-mRNA. J Biol Chem 2003; 
28:15825-31.
 23. Singh NK, Singh NN, Androphy EJ, Singh RN. Splicing of a critical exon of human sur-
vival motor neuron is regulated by a unique silencer element located in the last intron. Mol 
Cell Biol 2006; 26:1333-46.
 24. Skordis LA, Dunckley MG, Yue B, Eperon IC, Muntoni F. Bifunctional antisense oligo-
nucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression 
in patient fibroblasts. Proc Natl Acad Sci USA 2003; 100:4114-9.
 25. Cartegni L, Krainer AR. Correction of disease-associated exon skipping by synthetic 
exon-specific activators. Nat Struct Biol 2003; 10:120-5.
 26. Baughan T, Shababi M, Coady TH, Dickson AM, Tullis GE, Lorson CL. Stimulating 
full-length SMN2 expression by delivering bifunctional RNAs via a viral vector. Mol Ther 
2006; 14:54-62.
 2. Marquis J, Meyer K, Angehrn L, Kampfer SS, Rothen-Rutishauser B, Schumperli D. Spinal 
muscular atrophy: SMN2 pre-mRNA splicing corrected by a U snRNA derivative carrying 
a splicing enhancer sequence. Mol Ther 200; doi:10.1038/sj.mt.6300200.
 28. Madocsai C, Lim SR, Geib T, Lam BJ, Hertel KJ. Correction of SMN2 pre-mRNA splicing 
by antisense U small nuclear RNAs. Mol Ther 2005; 12:1013-22.
10 RNA Biology 200; Vol. 4 Issue 1
D
ow
nl
oa
de
d 
by
 [I
ow
a S
tat
e U
niv
ers
ity
] a
t 0
7:2
1 1
0 F
eb
ru
ary
 20
16
 
